Aa
A
A
Close
471014 tn?1207435481
telaprevir
Hi everyone,
I am reading up on telaprevir but found that so far there are only tests done with treatment naive patients (in France?!) I have been reading that for non-responders or relapsers this will only be an option in 3 to 5 years- on the other hand I hear from some of you that this is not the case for some of you - who can give me some info???
thanks in advance Béatrice
Cancel
6 Answers
Page 1 of 1
220090 tn?1379170787
Vertex has an ongoing trial for non--responders and relapsers.  They refer to is as Prove 3.  It is a phase 2 trial in FDA terminology.  

Vertex is about to start a phase 3 trial (confusing since they called the phase 2 trial Prove 3) and I believe, but I am not sure, that it will include relapsers and non responders.  There are rumors that Vertex will apply for approval of the drug based on the success of the Prove 3 trial.  These are not substantiated, so it is anyones guess about when the drug will be available to the general public.  Some people talk about 2010 - 2011 time frame.
Comment
Cancel
Comment
Avatar universal
Comment
Comment
Submit Comment
471014 tn?1207435481
thank you for this information
Comment
Cancel
Comment
Avatar universal
Comment
Comment
Submit Comment
201379 tn?1319994931
The trial current listed on the clinical trials website is treatment naive only.  The trial for non-responders and relapsers comes later, but may be entirely done in Europe.  Keep your ears open and your eyes peeled.

"mom"
Comment
Cancel
Comment
Avatar universal
Comment
Comment
Submit Comment
471014 tn?1207435481
Hi "mom",
where did you get this info? can you send me the link please?
(as I am in Europe!)
best greeting Béatrice
Comment
Cancel
Comment
Avatar universal
Comment
Comment
Submit Comment
104550 tn?1237917191
You can go to there web site @ vertex.com

- First hepatitis C protease inhibitor to begin Phase 3 clinical development - - Trial designed to confirm potential of telaprevir to increase sustained viral response (SVR) rates with 24-week treatment duration -

CAMBRIDGE, Mass., Mar 13, 2008 (BUSINESS WIRE) -- Vertex Pharmaceuticals Incorporated (Nasdaq: VRTX) and Tibotec today announced that patient screening has begun in the ADVANCE study, a pivotal Phase 3 clinical study with the hepatitis C virus (HCV) protease inhibitor telaprevir in combination therapy for treatment-naive patients with chronic HCV infection. Telaprevir is the most advanced HCV protease inhibitor in clinical development targeting treatment of hepatitis C, a disease that afflicts more than 3 million people in the United States alone, and 170 million worldwide. The ADVANCE trial will enroll 1,050 treatment-naive genotype 1 HCV patients and will evaluate two 24-week telaprevir-based regimens in comparison to a 48-week control arm. The primary endpoint of the study is sustained viral response (SVR), defined as undetectable HCV RNA (<10 IU/mL) 24 weeks after the completion of treatment. In this study, rapid viral response (RVR) criteria will be used to determine which telaprevir patients can stop all treatment at 24 weeks.

"This is the first Phase 3 study conducted to evaluate whether an investigational medicine for HCV may be able to both increase the rate of sustained viral response and shorten the duration of therapy to 24 weeks in patients with genotype 1 HCV infection compared to current treatment of 48 weeks. This is important given the expectation that approximately 40 to 50 percent of people with genotype 1 HCV who undergo treatment with current therapies achieve SVR," said John McHutchison, M.D., Associate Director, Duke Clinical Research Institute and a principal investigator for the ADVANCE study. "We're interested to see whether this trial will confirm the encouraging results seen thus far in Phase 2 studies of telaprevir. This study is another important step forward in the evaluation of novel medicines for the treatment of HCV."

"Following discussions with the U.S. FDA in January, we have been able to rapidly finalize the Phase 3 pivotal trial protocol and begin patient screening at the first sites," said John Alam, M.D., Executive Vice President, Medicines Development and Chief Medical Officer of Vertex. "The initiation of the ADVANCE trial underscores our commitment to evaluating the potential for telaprevir to address significant unmet medical needs in HCV."

The ADVANCE Study

The ADVANCE study (A New Direction in HCV Care: A Study of Treatment-Naive Hepatitis C Patients with telaprevir) will be conducted at more than 100 centers in the U.S., E.U. and certain other countries. Patient recruitment is being initiated in the U.S., while sites in other countries will start recruitment as national Clinical Trial Applications (CTAs) for each country are approved. The study arms will include:

Comment
Cancel
Comment
Avatar universal
Comment
Comment
Submit Comment
104550 tn?1237917191
Correction = vrtx.com to get to vertex web site
Comment
Cancel
Comment
Avatar universal
Comment
Comment
Submit Comment
Your Answer
Avatar universal
Answer
Know how to answer? Tap here to leave your answer...
Answer
Submit Answer
A
A
Recent Activity
317787 tn?1468754865
Blank
Dee1956 NEW SURVEY, top of page, pl... Comment
17 hrs ago
317787 tn?1468754865
Blank
10356, and Dee1956 commented on VICourageous's status
19 hrs ago
406584 tn?1399591666
Blank
10356 commented on stilltrying1965's status
19 hrs ago
Blank
Weight Tracker
Track your weight over time
Start Tracking Now
Top Hepatitis Answerers
317787 tn?1468754865
Blank
DC
163305 tn?1333672171
Blank
Rural Mural, CA
446474 tn?1446351282
Blank
San Francisco, CA
Avatar universal
Blank
1747881 tn?1358189534
Blank
Greeley, CO
2059648 tn?1439770265
Blank
Hepatitis C Community Resources